News · 26 weeks74+500%
2026-03-012026-08-23
Mix3190d
- Insider22(71%)
- Other3(10%)
- SEC Filings3(10%)
- Market2(6%)
- Earnings1(3%)
Latest news
25 items- INSIDERDirector Agee Nancy H bought $24,662 worth of shares (3,411 units at $7.23), increasing direct ownership by 1% to 309,187 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Legal Officer Lehr Donald P. converted options into 5,208 shares and covered exercise/tax liability with 2,488 shares, increasing direct ownership by 0.36% to 758,181 units (SEC Form 4) (tax liability)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Financial Officer Thomasian Harry Jr. converted options into 7,291 shares and covered exercise/tax liability with 3,577 shares, increasing direct ownership by 1% to 258,249 units (SEC Form 4) (withholding obligation)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Operating Officer Shah Rutul R exercised 57,500 shares at a strike of $2.03, sold $375,000 worth of shares (50,000 units at $7.50) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,647 shares, increasing direct ownership by 0.83% to 468,865 units (SEC Form 4) (withholding tax)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Commercial Officer Tennant Phil exercised 84,374 shares at a strike of $1.51, covered exercise/tax liability with 2,585 shares and sold $593,745 worth of shares (79,166 units at $7.50) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 141,992 units (SEC Form 4) to satisfy withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERPresident and CEO Sabzevari Helen converted options into 20,833 shares and covered exercise/tax liability with 10,184 shares, increasing direct ownership by 0.28% to 3,779,521 units (SEC Form 4) to satisfy withholding obligation4 - PRECIGEN, INC. (0001356090) (Issuer)
- NEWSPrecigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven CancersBiotech in the News: The LongviewThe Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability. Validated PlatformPresident and CEO Helen Sabzevari, PhD, framed the q
- INSIDERChief Operating Officer Shah Rutul R sold $224,590 worth of shares (32,739 units at $6.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 465,012 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- SECSEC Form 10-Q filed by Precigen Inc.10-Q - PRECIGEN, INC. (0001356090) (Filer)
- SECPrecigen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PRECIGEN, INC. (0001356090) (Filer)
- PRPrecigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue GrowthPAPZIMEOS® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and broad US adoptionPAPZIMEOS revenue propelled the Company to quarterly profitabilityCash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which together with proceeds from PAPZIMEOS revenue, is expected to support cash flow break-even by the end of 2026PAPZIMEOS patient hub enrollment reached well over 500 patients across major centers and community practices, demonstrating expanding reach and ease of administration across treatment settingsFDA granted PAPZIMEOS seven-year market exclusivity, providing long-term p
- INSIDERChief Operating Officer Shah Rutul R exercised 33,772 shares at a strike of $2.33 and sold $219,518 worth of shares (33,772 units at $6.50) as part of a pre-agreed trading plan (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Financial Officer Thomasian Harry Jr. sold $606,000 worth of shares (100,000 units at $6.06) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 254,535 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- PRPrecigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call
- INSIDERChief Financial Officer Thomasian Harry Jr. sold $1,113,143 worth of shares (200,000 units at $5.57) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 354,535 units (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Operating Officer Shah Rutul R exercised 42,924 shares at a strike of $2.33 and sold $251,105 worth of shares (42,924 units at $5.85) as part of a pre-agreed trading plan (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERPresident and CEO Sabzevari Helen exercised 346,836 shares at a strike of $2.33 and sold $2,042,864 worth of shares (346,836 units at $5.89) as part of a pre-agreed trading plan (SEC Form 4)4 - PRECIGEN, INC. (0001356090) (Issuer)
- SECPrecigen Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PRECIGEN, INC. (0001356090) (Filer)
- NEWSPrecigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study EncouragingMeg Flippin, Benzinga Staff WriterData reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patie
- PRPrecigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community VoicesThird annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRPGERMANTOWN, Md. and FORT WORTH, Texas, June 11, 2026 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the Recurrent Respiratory Papillomatosis Foundation (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day. Observed each year
- INSIDERChief Financial Officer Thomasian Harry Jr. sold $182,614 worth of shares (41,884 units at $4.36), decreasing direct ownership by 7% to 554,535 units (SEC Form 4) (withholding obligation)4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Commercial Officer Tennant Phil sold $131,986 worth of shares (30,272 units at $4.36), decreasing direct ownership by 18% to 139,369 units (SEC Form 4) to satisfy withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Operating Officer Shah Rutul R sold $186,185 worth of shares (42,703 units at $4.36), decreasing direct ownership by 8% to 497,751 units (SEC Form 4) to cover withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERChief Legal Officer Lehr Donald P. sold $127,011 worth of shares (29,131 units at $4.36), decreasing direct ownership by 4% to 755,461 units (SEC Form 4) to cover withholding tax4 - PRECIGEN, INC. (0001356090) (Issuer)
- INSIDERPresident and CEO Sabzevari Helen sold $519,930 worth of shares (119,250 units at $4.36), decreasing direct ownership by 3% to 3,768,872 units (SEC Form 4) (tax withholding)4 - PRECIGEN, INC. (0001356090) (Issuer)
PGEN FAQ
6 questionsWhat does Precigen Inc. do?
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs...Where does PGEN stock trade?
Precigen Inc. (PGEN) is listed on NASDAQ.What sector and industry is PGEN in?
Precigen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PGEN?
Precigen Inc. has had 4 recent analyst actions on file. The most recent action was from Analyst: Neutral on 2025-08-15. Recent price targets cluster around $700.00.What companies are similar to PGEN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PGEN side-by-side with any of them on Quantisnow.How can I track PGEN on Quantisnow?
Quantisnow aggregates Precigen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PGEN to receive live email and push alerts on every new disclosure.